TY -的T1 anticholineste停止响应rase agents in patients with MuSK-antibody-positive MG JF - Neurology JO - Neurology SP - 1508 LP - 1509 DO - 10.1212/01.wnl.0000183145.91579.74 VL - 65 IS - 9 AU - Y. Hatanaka AU - S. Hemmi AU - M. B. Morgan AU - M. L. Scheufele AU - G. C. Claussen AU - G. I. Wolfe AU - S. J. Oh Y1 - 2005/11/08 UR - //www.ez-admanager.com/content/65/9/1508.2.abstract N2 - Patients with seronegative myasthenia gravis (MG) often harbor antibodies for muscle-specific tyrosine kinase (MuSK).1 Nonresponsiveness or poor tolerability of anticholinesterase therapy has been mentioned in reports of this population2,3 but not comprehensively studied. We report anticholinesterase nonresponsiveness in 14 MuSK-antibody (Ab) positive patients seen at the University of Alabama at Birmingham (UAB) and University of Texas Southwestern Medical Center (UTSW), comparing them to MuSK-Ab-negative and acetylcholine receptor (AChR)-Ab seropositive patients from the UAB.Anticholinesterase hypersensitivity was defined when myasthenic symptoms worsened with medication; anticholinesterase intolerance when the patient developed severe cholinergic side effects with small doses of pyridostigmine or edrophonium, even with the administration of atropine or glycopyrrolate; and no improvement when there was no clinical benefit following administration of pyridostigmine. Hypersensitivity, intolerance, and no improvement were grouped together as anticholinesterase nonresponsiveness.At UAB, the AChR-Ab test was positive in 73 (72%) of 102 patients with generalized MG; the MuSK antibody test was positive in 7 (24%) of the … ER -